8-K: Onconetix to Acquire Ocuvex Therapeutics in Strategic Merger, Expanding Ophthalmic Pipeline

Onconetix, Inc. has entered into a definitive merger agreement to acquire Ocuvex Therapeutics, Inc., a privately held biopharmaceutical company, with Ocuvex equity holders set to own 90% of the combined entity post-closing.

Summary

• Onconetix, Inc. (ONCO) and Ocuvex Therapeutics, Inc. have signed a definitive merger agreement, under which Ocuvex will become a direct, wholly-owned subsidiary of Onconetix.
• Pre-closing Ocuvex stockholders are anticipated to own 90% of the combined company's fully diluted equity, while pre-closing Onconetix stockholders will own 10%, subject to adjustment for permitted financing.
• The combined company's board of directors will consist of seven members: five designated by Ocuvex (three independent) and two designated by Onconetix (one independent).
• Key management roles post-closing will include Antony Amato as CEO, David Friedman as President and COO, and Michael Proctor as EVP and CCO, all designated by Ocuvex.
• Onconetix regained compliance with Nasdaq's bid price and periodic reporting requirements as of July 7, 2025, following a 1-for-85 reverse stock split on June 13, 2025, and timely financial filings.
• Onconetix lowered the conversion price of its Series C Preferred Stock to $3.50 until July 31, 2025, with consent from all holders.
• Andrew Oakley was elected Lead Independent Director on July 12, 2025, with a monthly compensation of $36,000.
• The merger is subject to customary conditions, including regulatory, stockholder, and third-party approvals, and is anticipated to close in the fourth quarter of 2025.
• A 12.5% portion of the Merger Consideration (Parent Common Stock) will be held in a segregated escrow account for 18 months to satisfy indemnification obligations, excluding claims based on fraudulent, criminal, or intentional misconduct.

Sentiment

Score: 7

Explanation: The merger announcement is a significant strategic move for Onconetix, diversifying its portfolio with an FDA-approved product. Regaining Nasdaq compliance is also positive. However, the substantial dilution for existing Onconetix shareholders and the ongoing Nasdaq monitor introduce elements of risk and uncertainty, balancing the overall positive strategic direction.

Positives

• Strategic acquisition of Ocuvex Therapeutics, bringing a pipeline of commercial and late clinical stage ophthalmic assets, which is expected to bring significant value.
• Ocuvex's lead asset, Omlonti, received FDA approval in September 2022, indicating a commercial-stage product that diversifies Onconetix's portfolio.
• Onconetix has successfully regained compliance with Nasdaq listing criteria, ensuring continued listing on The Nasdaq Capital Market.
• The merger provides Ocuvex access to public capital markets, which is expected to accelerate the development of new treatment options.
• The transaction is intended to qualify as a tax-free reorganization under Section 368(a) of the Code.

Negatives

• Existing Onconetix shareholders will experience significant dilution, retaining only 10% of the combined entity on a fully diluted basis.
• Onconetix is subject to a Mandatory Panel Monitor by Nasdaq through July 7, 2026, which imposes stricter delisting rules for future non-compliance.
• The transaction is subject to various conditions, including regulatory, stockholder, and third-party approvals, with no assurance that it will be completed as proposed, or at all.
• Onconetix's present need for capital to commercially launch Proclarix and maintain adequate working capital is highlighted as a risk.
• The company's reliance on third parties, including manufacturers and logistics companies, is a potential vulnerability.

Risks

• Uncertainty regarding the completion of the Proposed Transaction, which may occur with different terms, in an untimely manner, or not at all.
• Risks related to Onconetix's ability to integrate Ocuvex's assets and commercial operations into its business.
• Market and other general economic conditions could adversely affect the combined company.
• Risks related to Onconetix's ability to commercialize or monetize Omlonti or its other products.
• Onconetix's present need for capital to commercially launch Proclarix and maintain adequate working capital.
• Risks related to Onconetix's ability to attract, hire, and retain skilled personnel necessary for commercialization and operations.
• Failure to obtain and maintain necessary regulatory approvals for marketing and commercializing products.
• Risks related to obtaining and maintaining intellectual property protection for Omlonti or other products.
• Risk of failing to maintain compliance with Nasdaq's applicable listing criteria and the potential effect of a delisting.
• Reliance on third parties, including manufacturers and logistics companies.
• Potential for indemnification claims against Ocuvex stockholders, with 12.5% of merger consideration held in escrow.
• The condition for Ocuvex to close is the restructuring of certain outstanding indebtedness of Parent (Veru Indebtedness).

Future Outlook

The Proposed Transaction is anticipated to close in the fourth quarter of 2025, subject to customary conditions. The merger is expected to provide Ocuvex access to public capital markets to accelerate the development and commercialization of new treatment options for patients. Onconetix aims to integrate Ocuvex's ophthalmic assets, including FDA-approved Omlonti, into its business, while also continuing to market its prostate cancer diagnostic test, Proclarix, in the U.S. as a lab-developed test.

Management Comments

• Andrew J. Oakley, Chairman of the Board of Onconetix, stated, 'We continue to believe that the proposed transaction with Ocuvex, which brings a pipeline of commercial and late clinical stage ophthalmic assets, will bring significant value for our stockholders.'
• Anthony W. Amato, Chairman and CEO of Ocuvex, commented, 'Gaining access to public capital markets will allow us to accelerate, what we believe to be, important new treatment options for patients and their health care providers. We would look forward to closing the transaction as it will be a major step forward for our company and our stakeholders.'

Industry Context

This merger represents a strategic move for Onconetix to diversify its portfolio beyond men's health and oncology diagnostics into the ophthalmic therapeutic market, a sector with high prevalence diseases and a need for new treatment options. By acquiring Ocuvex, which has an FDA-approved product (Omlonti), Onconetix gains immediate entry into a new commercial-stage therapeutic area, potentially leveraging Ocuvex's expertise and pipeline to expand its market presence. This aligns with a broader trend in the biopharmaceutical industry where companies seek to acquire specialized assets to enhance their product offerings and market reach.

Comparison to Industry Standards

• Ocuvex's lead asset, Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, an EP2 receptor agonist for ocular hypertension and open-angle glaucoma, received FDA approval in September 2022. This FDA approval is a significant milestone, indicating the product has met rigorous safety and efficacy standards for market entry in the U.S.
• Onconetix's Proclarix, an in vitro diagnostic test for prostate cancer, is approved for sale in the European Union (EU) under the IVDR and is anticipated to be marketed in the U.S. as a lab developed test (LDT) through a license agreement with Labcorp. This dual market approach (EU approval, US LDT) is a common strategy for diagnostic companies.

Management Changes

Corporate Governance

Legal Proceedings

• No new legal proceedings are announced. Onconetix successfully resolved a Nasdaq Hearings Panel matter regarding continued listing compliance, regaining compliance as of July 7, 2025.

Related Party Transactions

• The document mentions 'Related Party Contract' in its definitions and representations, but no specific related party transactions are disclosed in the main body of the 8-K or the merger agreement excerpts provided, beyond general statements about compliance with disclosure requirements.

Stakeholder Impact

• Shareholders (Onconetix): Significant dilution (from 100% to 10% ownership) but potential for value creation through the acquisition of a commercial-stage ophthalmic asset and diversification. Subject to a 1-for-85 reverse stock split.
• Shareholders (Ocuvex): Will become majority owners (90%) of a publicly traded company, gaining access to public capital markets. Subject to 6-month lock-up agreements on their newly acquired shares.
• Management/Employees: New management team for the combined entity, primarily from Ocuvex, indicating a shift in leadership. Andrew Oakley's role as Lead Independent Director is enhanced.
• Customers/Patients: Potential for accelerated development and commercialization of new ophthalmic treatment options (Omlonti) and continued marketing of prostate cancer diagnostic (Proclarix).
• Creditors: The restructuring of Veru Indebtedness is a condition for the merger, indicating potential impact on existing creditors.

Next Steps

• Onconetix to prepare and file a registration statement on Form S-4 (including proxy statement and prospectus) with the SEC.
• Onconetix to seek approval from its stockholders for the amendment and restatement of its certificate of incorporation and the issuance of merger consideration.
• Ocuvex to deliver PCAOB-audited financial statements for fiscal years ended December 31, 2023, and December 31, 2024, to Onconetix.
• The merger is anticipated to close in the fourth quarter of 2025.
• Parent and Company to use reasonable best efforts to enter into Transaction Financing agreements.
• Parent to cause its board of directors to consist of seven directors post-closing, with five designated by Ocuvex and two by Parent.
• Parent to appoint Antony Amato as CEO, David Friedman as President and COO, and Michael Proctor as EVP and CCO post-closing.
• Parent and the Surviving Corporation to maintain directors and officers liability insurance for six years post-closing.

Key Dates

Keywords

Merger Agreement, Biopharmaceutical, Ophthalmic Therapeutics, SEC Filing, Nasdaq Compliance, Stock Split, FDA Approval, Corporate Governance, Capital Raise, Oncology, Men's Health, Prostate Cancer, Glaucoma, Ocular Hypertension, Omlonti, Proclarix, SEC Form 8-K